| Business Summary | | Collateral
Therapeutics,
Inc.
is
focused
on
the
discovery
and
development
of
non-surgical
gene
therapy
products
for
the
treatment
of
cardiovascular
diseases,
including
coronary
artery
disease,
peripheral
vascular
disease,
congestive
heart
failure
and
heart
attacks.
The
Company's
initial
gene
therapy
products
are
designed
to
promote
and
enhance
angiogenesis,
a
natural
biological
process
that
results
in
the
growth
of
additional
blood
vessels
to
increase
levels
of
blood
flow
to
oxygen-deprived
tissues.
In
collaboration
with
its
partner,
Schering
AG,
in
May
1998,
the
Company
began
early
stage
testing
in
humans,
known
as
a
Phase
I/II
trial,
for
Generx,
the
first
of
its
gene
therapy
product
candidates.
In
January
2001,
based
on
results
from
the
Phase
I/II
trial,
Collateral
reported
plans
to
proceed
with
Phase
IIb/III
clinical
trials
of
Generx.
Its
non-surgical
gene
therapy
product
candidates
use
technology
that
includes
methods
of
gene
therapy,
therapeutic
genes
and
gene
delivery
vectors. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Collateral
Therapeutics
is
focused
on
the
discovery,
development
and
commercialization
of
non-surgical
gene
therapy
products
for
the
treatment
of
cardiovascular
diseases.
For
the
six
months
ended
6/30/01,
revenues
fell
14%
to
$1.2
million.
Net
loss
increased
26%
to
$8.2
million.
Revenues
reflect
decreased
R
and
D
support
to
the
company
under
the
Schering
AG
agreement.
Higher
loss
also
reflects
increases
in
personnel
costs,
lab
supplies
and
rent
expense. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Jack Reich, Ph.D., 52 CEO,
Chairman | $686K | -- | Christopher Reinhard, 47 Pres,
COO, Chief Financial Officer, Director | 487K | -- | Tyler Dylan, Ph.D., 39 VP,
Gen. Counsel, Sec. | 284K | -- | Jeffrey Friedman, M.D., 54 VP-
Devel. | 295K | $7.1K | Patricia Novak, Ph.D., 49 VP,
Product Management | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|